相关实验视频

Updated: Jun 8, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

针对EGFR向疗法的初级耐药性的假定机制:一项回顾性研究

Xueliang Tu¹, Zhongyu Lu², Fengrong Hei³

¹Department of Clinical Laboratory, Yellow River Sanmenxia Affliated Hospital of Henan University of Science and Technology, Sanmenxia, PR China.

Lung cancer (Amsterdam, Netherlands)

|November 3, 2024

概括

晚期肺腺癌 (LUAD) 中对EGFR-TKI的初级耐药性与特定的基因突变有关. 识别这些基因组变异,如PIK3C2G和STK11,可以为LUAD患者指导个性化治疗策略.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
个性化医疗是个性化的医疗.

背景情况:

患有EGFR突变的高级肺腺癌 (LUAD) 患者通常会对一线EGFR-TKI产生抗性.
对EGFR-TKI初级耐药性的机制和生物标志物尚不清楚.
确定预后因素对于定制LUAD治疗策略至关重要.

研究的目的:

调查与LUAD患者对一线EGFR-TKI的初级耐药性相关的基因组景观.
为了确定潜在的生物标志物来预测对EGFR-TKI治疗的反应.

主要方法:

对124名具有常见EGFR敏感性突变的IV期LUAD患者进行了回顾性研究,这些患者接受一线EGFR-TKI治疗.
基线样本的DNA向测序,以分析基因组变化.
患者被分为初级耐药性 (PFS ≤3个月),不良反应 (3

主要成果:

最常见的突变是TP53,MYC,CDKN2A,MUC16和RBM10.这些突变是最常见的突变.
在初级耐药组中,PIK3C2G,STK11,EPAS1,RARA和BTG2变异的频率明显高于初级耐药组.
多变量分析发现PIK3C2G,STK11,EPAS1和BTG2放大与较短的无进展生存期 (PFS) 有显著关联.

结论:

患者的基因组格局显著影响治疗决策.
特定的基因变异 (PIK3C2G,STK11,EPAS1,BTG2) 与对EGFR-TKI的初级耐药性有关.
了解这些分子变化可以为患有EGFR突变的LUAD患者提供个性化的治疗信息.

关键词:

在DNA测序过程中,DNA测序欧洲农业基金的技术技能.肺部腺癌瘤是肺部腺癌.主要电阻的主要电阻.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...